Business & Finance Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
By
· October 29, 2026 · 1 min read
This article was originally published by
CNBC Top News
and is republished here under license.
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
Related
While the industry is on track for its highest number of launches, a more sobering threshold is in sight as well. …
By
· October 29, 2026 · 1 min read
“Given the size and long-term nature of this gift, we want to make sure the funds are managed prudently.”…
By
· October 29, 2026 · 1 min read
Más de 660 fondos invertían en acciones latinoamericanas en 2015. Hoy quedan apenas 226. El prolongado declive refleja una región…
By
· October 29, 2026 · 1 min read
Leave a Reply